Navigation Links
Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint

h the use of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for the treatment of chronic hepatitis B and the safety and efficacy of Viread have not been established in patients coinfected with HBV and HIV. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued Viread. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are co-infected with HIV and HBV and discontinue Viread. If appropriate, initiation of anti-hepatitis B therapy may be warranted.

Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported in association with the use of Viread. It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy with Viread and as clinically appropriate during therapy. Coadministration of Viread and didanosine should be undertaken with caution. Patients should be monitored closely for didanosine-associated adverse events, and didanosine should be discontinued if these occur. Patients on atazanavir and lopinavir/ritonavir plus Viread should be monitored for Viread-associated adverse events, and Viread should be discontinued if these occur. When co-administered with Viread, it is recommended that atazanavir 300 mg be given with ritonavir 100 mg. Atazanavir without ritonavir should not be co-administered with Viread.

Decreases in bone mineral density (BMD) at the lumbar spine and hip have been seen with the use of Viread. The effects of Viread-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk are unknown. Changes in body fat have been observed in patients taking anti-HIV medicines. The cause and long-term health effect of these changes are unknown. Immune Reconstitution Syndrome has been reported in patients treated with combination therapy, including Viread.

The m
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
4. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
5. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
6. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
10. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
Post Your Comments:
(Date:6/30/2015)... Millar, Inc. , a leader in catheter-based and wireless ... Craig Thummel , President/CEO and member of the ... the Company. The Company also announced its leadership succession ... Management team as his successors. The Board of Directors ... Sales and Marketing, as President, and also a member ...
(Date:6/30/2015)... CENTER VALLEY, Pa. , June 30, 2015 ... designing and delivering innovative solutions for medical and ... it is guaranteeing next-day replacements for surgical equipment ... surgical product manufacturer to offer this type of ... an Olympus Full Service Agreement earlier this year. ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... gastrointestinal and metabolic diseases, today announced that the Company ... 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an overview ... tenapanor, which has completed Phase 2b clinical trials for ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 2Olympus Introduces Industry-First Next-Day Product Replacement Guarantee for Surgical Business 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2
... - Novel, ... 15 Carrington,Laboratories, Inc. (Nasdaq: CARN ) today ... toxicology studies of its,GelVac(TM) nasal powder influenza vaccine, incorporating ... a critical step during the vaccine,development and will assess ...
... N.C., Aug. 16 Cancer patients fraught with,flare-ups ... some assistance,in the form of a new easy-to-use ... to quickly deliver pain medication. Cancer patients ... Persistent cancer pain is characterized as continuous pain,present ...
Cached Medicine Technology:Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine 2Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine 3Novel Technology Breaks Through Cancer Pain 2
(Date:6/30/2015)... Columbus, Ohio (PRWEB) , ... June 30, 2015 ... ... management services nationwide, announces today that they have been awarded the exclusive billing ... deliver a full range of billing services encompassing their proprietary suite of billing ...
(Date:6/30/2015)... New York, NY (PRWEB) , ... June 30, ... ... international shipping when buying eyeglasses online , finally its here, ... and offer express shipping rates, for many location, ask about shipping with DHL ...
(Date:6/30/2015)... ... ... Dr. Sammy Masri of Masri Sports Medicine &Wellness, NJ Top Doc, is ... treatment of non-surgical sports and other musculoskeletal injuries for both adults and children, for ... exercise to stay healthy and active. Dr. Masri seeks to provide his patients with ...
(Date:6/30/2015)... ... June 30, 2015 , ... Red Hot & Blue Restaurants, Inc. ... at http://scoutology.com/novaburgerwars and was selected as “Best BBQ” in a Texas-based ... Red Hot & Blue President Randy McCann said, “Everyone knows Red Hot & Blue ...
(Date:6/30/2015)... ... June 30, 2015 , ... After more than five ... and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for the unique skin of ... of 35, hits the market just in time to help protect the skin of ...
Breaking Medicine News(10 mins):Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 2Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 3Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 4Health News:NJ Top Docs Presents Dr. Sammy Masri; Dr. Masri is Now Offering a Wide Range of Services to his Valued Patients 5Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2
... explain why breast-fed infants less likely to be overweight later ... bacteria in a baby,s gut may predict whether that infant ... study suggests. , Babies with high numbers of bifidobacteria and ... from excess weight gain, according to a team of researchers ...
... Publishing and Penn,Hill Publications, based in Waltham, MA, ... News Media Contacts Directory. In addition to,publishing the ... Grey House is also proud to announce a ... In 1968, Howard Penn Hudson completed years of ...
... FAIRFAX, Va., March 5, 2008--Worldwide, an average 95.4 percent ... according to the first review of the world body ... Refractive Surgery (ASCRS) announced today. , With 16.3 ... a decade of clinical study and technological innovation behind ...
... scores, study finds , , FRIDAY, March 7 (HealthDay News) ... children,s physical and mental development, a U.S. study concludes. ... found that children in low-income families in Mexico who ... conditional cash transfer program were taller, less likely to ...
... YORK, March 7 Four out of every ... supplement every day, according to the,Institute of Medicine. ... are made due to handwritten prescriptions. These errors ... interactions and,allergic reactions., See video from ...
... patient care, research and teaching at ... the Medical Center, ... new jobs over the last six years accounting,for nearly 50 percent of ... Top 20 employers reduced jobs, says an economic,impact report released today by ...
Cached Medicine News:Health News:Bacteria Mix in Guts of Babies Predicts Obesity 2Health News:Bacteria Mix in Guts of Babies Predicts Obesity 3Health News:Grey House Publishing Acquires Hudson's Washington News Media Contacts Directory 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 3Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 4Health News:Government Assistance Linked to Better Child Development 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 2Health News:Chamber Analysis Shows OSU Medical Center Leads Area Job Growth 3
... determines osmolality at room temperature with the ... get are cryoscopic artifacts due to high ... interfere with freezing point determinations. The superbly ... Vapro osmometer has a much broader range ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... in specimen radiography. The XPERT represents a research ... of gray in every digital x-ray image, thus ... density that heretofore were lost to the human ... x 2 to 8 x 8 in size, ...
Medicine Products: